Specific Sirt1 Activator-mediated Improvement in Glucose Homeostasis Requires Sirt1-Independent Activation of AMPK
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The specific Sirt1 activator SRT1720 increases mitochondrial function in skeletal muscle, presumably by activating Sirt1. However, Sirt1 gain of function does not increase mitochondrial function, which raises a question about the central role of Sirt1 in SRT1720 action. Moreover, it is believed that the metabolic effects of SRT1720 occur independently of AMP-activated protein kinase (AMPK), an important metabolic regulator that increases mitochondrial function. Here, we show that SRT1720 activates AMPK in a Sirt1-independent manner and SRT1720 activates AMPK by inhibiting a cAMP degrading phosphodiesterase (PDE) in a competitive manner. Inhibiting the cAMP effector protein Epac prevents SRT1720 from activating AMPK or Sirt1 in myotubes. Moreover, SRT1720 does not increase mitochondrial function or improve glucose tolerance in AMPKα2 knockout mice. Interestingly, weight loss induced by SRT1720 is not sufficient to improve glucose tolerance. Therefore, contrary to current belief, the metabolic effects produced by SRT1720 require AMPK, which can be activated independently of Sirt1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
Jäger, S., Handschin, C., St.-Pierre, J., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705070104 · Cited by 2,491
Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys
Colman, R. J., Anderson, R. M., Johnson, S. C., Kastman, E. K., Kosmatka, K. J., Beasley, T. M., Allison, D. B., Cruzen, C., Simmons, H. A., Kemnitz, J. W., et al. (2009) · Science · doi:10.1126/science.1173635 · Cited by 2,277
The Effect of Retarded Growth Upon the Length of Life Span and Upon the Ultimate Body Size
McCay, C. M., Crowell, M. F., & Maynard, L. A. (1935) · The Journal of Nutrition · doi:10.1093/jn/10.1.63 · Cited by 2,264
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707 · cited 6×
“, 2015) and the serum concentration of SRT1720 in mice treated with SRT1720 (~1 μM) (Milne et al., 2007).”
BackgroundMethodInfluentialSelf-citationYoshino, J., Mills, K. F., Yoon, M. J., & Imai, S.-I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.014 · Cited by 1,340
Cantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 1×
“Indeed, treatment with NAD+ precursors such as nicotinamide mononucleotide or nicotinamide ribose increase intracellular NAD+ levels and confer metabolic benefits (Canto et al., 2012; Gomes et al., 2013; Mouchiroud et al., 2013; Pirinen et al., 2014; Yoshino et al., 2011).”
BackgroundMouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210 · cited 1×
“Indeed, treatment with NAD+ precursors such as nicotinamide mononucleotide or nicotinamide ribose increase intracellular NAD+ levels and confer metabolic benefits (Canto et al., 2012; Gomes et al., 2013; Mouchiroud et al., 2013; Pirinen et al., 2014; Yoshino et al., 2011).”
BackgroundMechanism of Human SIRT1 Activation by Resveratrol
Borra, M. T., Smith, B. C., & Denu, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501250200 · Cited by 1,065 · cited 5×
“SRT1720 is now the most widely used Sirt1-specific activator.”
BackgroundInfluentialSIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α
Nemoto, S., Fergusson, M. M., & Finkel, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501485200 · Cited by 1,047
SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1
Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R. S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088682 · Cited by 915 · cited 9×
“However, the question ofwhether SRT1720 exerts itsmetabolic effects by directly activating Sirt1 still remains unanswered (Dai et al., 2010; Huber et al., 2010; Pacholec et al., 2010).”
BackgroundResultInfluentialSIRT1 Modulation of the Acetylation Status, Cytosolic Localization, and Activity of LKB1
Lan, F., Cacicedo, J. M., Ruderman, N., & Ido, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805711200 · Cited by 825
Substrate-specific activation of sirtuins by resveratrol
Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500655200 · Cited by 745
SIRT1 transgenic mice show phenotypes resembling calorie restriction
Bordone, L., Cohen, D., Robinson, A., Motta, M. C., Van Veen, E., Czopik, A., Steele, A. D., Crowe, H., Marmor, S., Luo, J., et al. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00335.x · Cited by 722 · cited 2×
“…Medicine Group, Basic & , The University of Melbourne, ss article under the CC BY license (ht 2005; Herranz et al., 2010), improve insulin sensitivity and protect against hepatic steatosis in transgenic mice (Banks et al., 2008; Bordone et al., 2007; Boutant et al., 2016; Pfluger et al., 2008).”
BackgroundFeige, J. N., Lagouge, M., Canto, C., Strehle, A., Houten, S. M., Milne, J. C., Lambert, P. D., Mataki, C., Elliott, P. J., & Auwerx, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.017 · Cited by 719 · cited 14×
“Feige et al. reported that SRT1720 does not activate AMPK in C2C12 myotubes (Feige et al., 2008), but the concentration of SRT1720 these authors used (0.01–0.05 μM) was significantly lower than the concentration used by others (1–10 μM) (Funk et al., 2010; Smith et al., 2009; Svensson et al., 2015)…”
BackgroundResultInfluentialSirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
Herranz, D., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., & Serrano, M. (2010) · Nature Communications · doi:10.1038/ncomms1001 · Cited by 612 · cited 1×
“…Guarente, ofMedicine, Dong-AUniversity, rative Medicine Group, Basic & , The University of Melbourne, ss article under the CC BY license (ht 2005; Herranz et al., 2010), improve insulin sensitivity and protect against hepatic steatosis in transgenic mice (Banks et al., 2008; Bordone et al.,…”
BackgroundRyall, J. G., Dell’Orso, S., Derfoul, A., Juan, A., Zare, H., Feng, X., Clermont, D., Koulnis, M., Gutierrez-Cruz, G., Fulco, M., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2014.12.004 · Cited by 575
Self-citationThe AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity
Viollet, B., Andreelli, F., Jørgensen, S. B., Perrin, C., Geloen, A., Flamez, D., Mu, J., Lenzner, C., Baud, O., Bennoun, M., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16567 · Cited by 499 · cited 2×
“AMPK α2−/− (Viollet et al., 2003) mice were backcrossed to C57BL/6J for at least six generation before this study.”
MethodAMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458 · cited 1×
“There is a complex interrelationship between Sirt1 andAMP-activated kinase (AMPK), which regulates energy balance by stimulating pathways involved in mitochondrial biogenesis, energy production and glucose uptake and suppressing glucose production (Hardie, 2013).”
BackgroundResveratrol is not a direct activator of SIRT1 enzyme activity
Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S., Atangan, L., & Wang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00901.x · Cited by 426 · cited 1×
“However, a number of groups observed that STACs did not activate Sirt1 if the substrate peptide was not tagged with a fluorophore (Beher et al., 2009; Borra et al., 2005; Dai et al., 2010; Hubbard et al., 2013; Kaeberlein et al., 2005; Pacholec et al., 2010).”
BackgroundWalker, A. K., Yang, F., Jiang, K., Ji, J.-Y., Watts, J. L., Purushotham, A., Boss, O., Hirsch, M. L., Ribich, S., Smith, J. J., et al. (2010) · Genes & Development · doi:10.1101/gad.1901210 · Cited by 357 · cited 2×
“…mitochondrial biogenesis, energy metabolism and glucose tolerance (Feige et al., 2008; Milne et al., 2007); decreased hepatic lipid accumulation (Walker et al., 2010; Yamazaki et al., 2009) and extended the tp://creativecommons.org/licenses/by/4.0/). lifespan in mice (Minor et al., 2011b;…”
BackgroundInfluentialPirinen, E., Cantó, C., Jo, Y. S., Morato, L., Zhang, H., Menzies, K. J., Williams, E. G., Mouchiroud, L., Moullan, N., Hagberg, C., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.002 · Cited by 254 · cited 2×
“Indeed, treatment with NAD+ precursors such as nicotinamide mononucleotide or nicotinamide ribose increase intracellular NAD+ levels and confer metabolic benefits (Canto et al., 2012; Gomes et al., 2013; Mouchiroud et al., 2013; Pirinen et al., 2014; Yoshino et al., 2011).”
Background
Cited by
Sirtuin activators and inhibitors: Promises, achievements, and challenges
Dai, H., Sinclair, D. A., Ellis, J. L., & Steegborn, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.004 · Cited by 463
“The natural STAC resveratrol suffered from low bioavailability and potency, and - like early synthetic STACs such as SRT1720 – from limited target specificity (Pirola and Frojdo, 2008; Huber et al., 2010; Nguyen et al., 2013b; Park et al., 2017).”
BackgroundEgan, B., & Sharples, A. P. (2023) · Physiological Reviews · doi:10.1152/physrev.00054.2021 · Cited by 278
Emerging Role of cAMP/AMPK Signaling
Aslam, M., & Ladilov, Y. (2022) · Cells · doi:10.3390/cells11020308 · Cited by 241
SIRT1 activation promotes energy homeostasis and reprograms liver cancer metabolism
Varghese, B., Chianese, U., Capasso, L., Sian, V., Bontempo, P., Conte, M., Benedetti, R., Altucci, L., Carafa, V., & Nebbioso, A. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04440-9 · Cited by 31
“A previous study showed that pharmacological activation of SIRT1 improved glucose metabolism in an AMPKdependent posttranslational manner [48].”
Background
Metadata
- Authors
- Park, S.-J., Ahmad, F., Um, J.-H., Brown, A. L., Xu, X., Kang, H., Ke, H., Feng, X., Ryall, J., Philp, A., Schenk, S., Kim, M. K., Sartorelli, V., & Chung, J. H.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 18
- Pages
- 128-138
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2595625052
- Cited by
- 44
- References
- 21
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.